US20160129092A1 - Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function - Google Patents
Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function Download PDFInfo
- Publication number
- US20160129092A1 US20160129092A1 US14/876,004 US201514876004A US2016129092A1 US 20160129092 A1 US20160129092 A1 US 20160129092A1 US 201514876004 A US201514876004 A US 201514876004A US 2016129092 A1 US2016129092 A1 US 2016129092A1
- Authority
- US
- United States
- Prior art keywords
- dry powder
- powder composition
- feed
- weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 21
- 239000011707 mineral Substances 0.000 title claims abstract description 21
- 239000004927 clay Substances 0.000 title claims abstract description 20
- 230000036737 immune function Effects 0.000 title abstract description 16
- 239000005909 Kieselgur Substances 0.000 title abstract description 14
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 title abstract description 8
- 229920002581 Glucomannan Polymers 0.000 title abstract description 8
- 229940046240 glucomannan Drugs 0.000 title abstract description 8
- 229920001503 Glucan Polymers 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 25
- 241000271566 Aves Species 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 49
- 241001465754 Metazoa Species 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 26
- 229920002498 Beta-glucan Polymers 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 10
- 229920000057 Mannan Polymers 0.000 claims description 8
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 230000034994 death Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 241000282849 Ruminantia Species 0.000 claims description 2
- 206010052535 Small intestinal haemorrhage Diseases 0.000 claims description 2
- 206010000210 abortion Diseases 0.000 claims description 2
- 231100000176 abortion Toxicity 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 238000009991 scouring Methods 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims 7
- 235000015278 beef Nutrition 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 11
- 230000003416 augmentation Effects 0.000 abstract description 6
- 210000000440 neutrophil Anatomy 0.000 description 47
- 244000052769 pathogen Species 0.000 description 45
- 230000001717 pathogenic effect Effects 0.000 description 25
- 238000011282 treatment Methods 0.000 description 23
- 108010092694 L-Selectin Proteins 0.000 description 22
- 102000016551 L-selectin Human genes 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 14
- 102000002689 Toll-like receptor Human genes 0.000 description 13
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 12
- 102000003777 Interleukin-1 beta Human genes 0.000 description 12
- 108090000193 Interleukin-1 beta Proteins 0.000 description 12
- 108020000411 Toll-like receptor Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229910052570 clay Inorganic materials 0.000 description 11
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241001225321 Aspergillus fumigatus Species 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 210000005253 yeast cell Anatomy 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 5
- 244000053095 fungal pathogen Species 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000005007 innate immune system Anatomy 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000032696 parturition Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 229910021536 Zeolite Inorganic materials 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000010457 zeolite Substances 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 2
- 108010078015 Complement C3b Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101100369864 Bos taurus TLR4 gene Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000003353 pseudopodial effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A23K1/1643—
-
- A23K1/1653—
-
- A23K1/1756—
-
- A23K1/1813—
-
- A23K1/1826—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/294—Inorganic additives, e.g. silica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5034—Beta-Glucan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5058—Glucomannan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01006—Endo-1,3(4)-beta-glucanase (3.2.1.6)
Definitions
- This disclosure relates to methods and compositions for the augmentation of immune function in mammalian and avian species.
- the immune system consists of two general features. These are: 1) the innate immune system and 2) the adaptive (antibody-mediated) immune system.
- the innate system represents the first line of defense against an invading pathogen (whether bacterial or fungal) and provides the adaptive immune system with enough time (3-5 days) for it to build up antibodies which are used to “fight” pathogens. While the innate and adaptive systems are often described separately, they function in tandem; striving to sequester and neutralize a pathogen challenge.
- the innate immune system consists of several interesting components: Aspects include:
- Signaling molecules e.g., chemokines, cytokines which communicate sites of infection and regulate expression of immune genes.
- Neutrophils are among the most important cells of the innate immune system. They are the first cell to arrive at a site of infection. In mammals, there are billions of neutrophils of which about one-half are freely circulating in the blood (Burton and Erskine, 2003). The remainder are held in reserve in bone marrow where they are formed. Neutrophils express an extracellular binding protein on their membranes termed “L-selectin” (also termed CD62L). The role of L-selectin is to interact weakly with the endothelial cell wall thereby allowing the neutrophil to “roll” along the wall of a blood vessel and to “monitor” the cell wall for the presence of signals which indicate a local infection ( FIG. 1 ).
- neutrophil migration chemical signals originating from the site of infection (such as TNF- ⁇ and interferon y) activate the neutrophil to become a mature “killer cell”.
- the mature neutrophil migrates toward the site of infection where it interacts with pathogen-associated microbial patterns (PAMPs) on the surface of pathogens via several types of receptors. These receptors are expressed on the surface of the neutrophil and include the following well-identified types ( FIG. 2 ):
- TLRs Toll-like receptors
- TLRs toll-like receptors
- TLRs Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK ( FIG. 2 ). This signaling cascade leads to the activation of the transcription factor NF-kB which induces the secretion of cytokines that direct the adaptive (i.e., antibody-mediated) immune response.
- NF-kB transcription factor
- cytokines that direct the adaptive (i.e., antibody-mediated) immune response.
- TLRs are predominantly expressed in tissues involved in immune function, such as spleen and peripheral blood leukocytes, as well as those exposed to the external environment such as lung and the gastrointestinal tract. Ten human and nine mouse TLRs have been characterized, seven of which have had their ligands identified.
- TLR2 is essential for the recognition of a variety of PAMPs, including bacterial lipoproteins, peptidoglycan, and lipotechoic acids.
- TLR3 is implicated in virus-derived double-stranded RNA.
- TLR4 is predominantly activated by lipopolysaccharide.
- TLR5 detects bacterial flagellin and TLR9 is required for response to unmethylated CpG DNA (Table 1).
- Recently, TLR7 and TLR8 were shown to recognize synthetic antiviral molecules. These receptors are essential elements in host defense against pathogens by activating the innate immunity (Invivogen, 2004).
- Bovine TLRs Relatively few studies on PAMPs have been completed with bovine cells. So far, bovine immune cells have been reported to contain TLR2 and TLR4 (Werling et al., 2004). Polymorphisms have been reported in bovine TLR4 which may determine susceptibility to bovine respiratory disease and Johne's disease (White et al., 2003).
- C3b and C3bi are components of the complement cascade whereas the Fc receptor binds to the “constant region” of antibodies.
- pathogens which are coated with complement factors or antibody i.e., pathogens which are opsonized
- activated neutrophils possess several means by which they recognize pathogens (Table 1).
- Phagocytosis and killing The binding of neutrophils, (and other phagocytic cells) to cell-surface markers of pathogens via these receptors, then permits the phagocytic cell to engulf the invading pathogen and “kill” it ( FIG. 3 ).
- two mechanisms for “killing” are known. These include: 1) an oxidative burst, where the phagocyte expresses reactive oxygen species which destroy the phagocytosed pathogen, and 2) fusion of the engulfed pathogen with a lyso some-like structure to form a “phagosome”.
- the phagosome is rich in digestive enzymes which mediate complete digestion of pathogens.
- Antibodies which are specific to an invading pathogen leak into a site of infection to optimize clearance of a pathogen.
- Individuals with a high titer against a specific antigen are able to deliver these antibodies into the site of infection via a leaky endothelium (arising from an inflammatory response).
- the object of the present invention is to provide a novel and previously unknown method for augmentation of the immune system in mammalian and avian species.
- the invention may be applied to, but not limited to, mammalian and avian species and will reduce susceptibility of an individual to both fungal and bacterial diseases.
- a further object of this invention is to provide a method for augmentation of immune function and to thereby minimize or obviate morbidities and mortalities caused by, but not limited to, pathogenic fungi and bacteria with a preparation comprising a combination of ⁇ -1,3 (4)-endoglucanohydrolase, ⁇ -glucan, diatomaceous earth, glucomannan, and mineral clay, such as aluminum silicate, montmorillonite clay, bentonite or zeolite.
- Another object of the invention is to provide a composition comprising a combination of ⁇ -1,3 (4)-endoglucanohydrolase, ⁇ -glucan, diatomaceous earth, mineral clay, and glucomannan, which additively augments immune function and thereby, reduces potential of pathogenic fungi and bacteria to cause morbidities and mortalities in mammalian and avian species.
- this invention increases expression of neutrophil L-selectin and interleukin-1 ⁇ and thereby minimizes or eliminates the colonization of the epithelial surfaces and underlying parenchymal tissues by pathogenic fungi and bacteria, reduces the populations of pathogenic organisms in blood and thereby minimizes or eliminates pathologies directly caused by and indirectly caused by this colonization.
- the invention comprises a mixture of ⁇ -1,3 (4)-endoglucanohydrolase, ⁇ -glucan, diatomaceous earth, mineral clay, and glucomannan.
- the diatomaceous earth is standard commercial grade available from a variety of sources.
- the ⁇ -1,3 (4)-endoglucanohydrolase is produced from submerged fermentation of a strain of Trichoderma longibrachiatum .
- the ⁇ -1,3 (4)-glucan and glucomannan are derived from a commercial product and are an extraction from any of a number of yeast organisms.
- the mineral clay product is a standard commercial grade (examples include, but are not limited to, montmorillonite clay, bentonite and zeolite). Extractions and productions of diatomaceous earth, yeast cell wall extract and mineral clay are well known in the art and commercially-available.
- compositions which are provided by the invention can be fed to any mammalian or avian species including, but not limited to, bovine, equine, ovine, caprine and avian species.
- the invention augments immune function thereby reducing colonization by pathogens.
- the invention also minimizes or eliminates invasion of the blood compartment by pathogenic fungi and bacteria.
- the invention thereby minimizes or eliminates the manifestations of the pathologies typically associated with epithelial and systemic fungal and bacterial infections.
- Administration of the product may be used as a prophylactic (i.e., to prevent colonization and growth of pathogenic fungal and bacterial species in mammalian or avian species), as an additive to feeds or foods infected with pathogenic fungi or bacteria or as a preferred method to treat and thereby minimize or eliminate an existing, diagnosed or non-diagnosed, fungal or bacterial infection.
- Application of the invention as described herein and via the specific and novel mechanisms described herein will minimize and possibly eliminate manifestations of fungal and bacterial infections.
- Application of the invention as described herein will also minimize or possibly eliminate manifestations associated with the presence of pathogenic fungal and bacterial organisms, as identified above, in food or feed of mammalian and avian species.
- FIG. 1 is a schematic drawing illustrating the movement of neutrophils through a blood vessel.
- L-selectin CD62L
- FIG. 1 is a schematic drawing illustrating the movement of neutrophils through a blood vessel.
- L-selectin CD62L
- FIG. 1 is a schematic drawing illustrating the movement of neutrophils through a blood vessel.
- L-selectin CD62L
- FIG. 1 is a schematic drawing illustrating the movement of neutrophils through a blood vessel.
- L-selectin CD62L
- FIG. 1 is a schematic drawing illustrating the movement of neutrophils through a blood vessel.
- L-selectin CD62L
- FIG. 2 is a schematic diagram illustrating toll-like receptors (TLRs) on the surface of an immune cell, and signal transduction following binding of TLRs with microbial PAMPs (pathogen-associated molecular patterns).
- TLRs toll-like receptors
- FIG. 3 illustrates a macrophage cell engulfing a bacterium in a process called phagocytosis. Toll-like and other receptor direct phagocytes to recognize microbes. Pseudopodial projections surround the bacterium. (Source: Travis, 2002.)
- FIG. 4 is a bar graph of cortisol levels in dairy cattle relative to day of parturition. Cortisol peaks at day of parturition. (Source: Weber et al., 2001.)
- FIG. 5 is a bar graph of neutrophil surface CD62L (L-selectin) expression in cattle relative to day of parturition. (Source: Weber et al., 2001.)
- FIG. 6 is a schematic diagram illustrating neutrophils lacking L-selectin expression in a stressed dairy cow. (Source: Burton and Erskine, 2003.
- FIG. 7 Effect of five experimental treatments on concentrations of neutrophil L-selectin. An experiment was conducted with 60 sheep. Twelve sheep were allocated to each treatment. The treatments consisted of:
- the duration of the trial was 28-days. On Day 28, blood was taken from six sheep per treatment and neutrophils were recovered by Percoll gradient centrifugation. The concentrations of L-selectin were determined by Western blot analysis using an antibody specific to L-selectin. Relative concentrations of L-selectin among the five treatment groups are shown in FIG. 8 .
- FIG. 8 Scanning densitometry of data shown in FIG. 7 .
- FIG. 9 Analysis of neutrophil interleukin-1 ⁇ in the same sheep neutrophil samples presented in FIG. 7 .
- FIG. 10 Scanning densitometry of data shown in FIG. 9 .
- FIG. 11 Concentrations of Aspergillus fumigatus in blood samples taken from sheep on Day 28 of the above study. A. fumigatus DNA levels were assessed using a quantitative Sybr-Green PCR-based assay specific for A. fumigatus.
- the present invention is based on the novel discovery that a combination of ⁇ -1,3 (4)-endoglucanohydrolase, ⁇ -1,3 (4)-glucan, diatomaceous earth, mineral clay, and glucomannan effectively augments immune function and reduces colonization of tissues and blood by a pathogen.
- the ⁇ -1,3 (4)-endoglucanohydrolase is from a commercial source and is produced from submerged fermentation of a strain of Trichoderma longibrachiatum.
- the diatomaceous earth is prepared by methods commonly known in the art. It is available as a commercially-available acid-washed, product with 95% silica (SiO2) and with its remaining components not assayed but consisting primarily of ash (minerals) as defined by the Association of Analytical Chemists (AOAC, 2002).
- the yeast cell wall extract is prepared by a method commonly known in the art. It is a commercial source of ⁇ -1,3 (4) glucan and glucomannan derived from primary inactivated yeast ( Saccharomyces cerevisiae ) with the following chemical composition:
- the mineral clays (aluminosilicates) used in this invention may be fulfilled by any of a variety of commercially-available clays including, but not limited to, montmorillonite clay, bentonite and zeolite.
- ⁇ -1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.05-3%, 1-40%, 1-20% and 40-92%, respectively.
- ⁇ -1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.1-3%, 5-40%, 2-10% and 40-80%, respectively.
- ⁇ -1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.2-3%, 30-40%, 4-6% and 50-65%, respectively.
- the preferred physical form of the invention is a dry, free-flowing powder which is suitable for direct inclusion into a feed, food product or as a supplement to a total mixed ration or diet.
- compositions provided by the present invention may be incorporated directly into commercially-available feeds or food products or fed as supplements to commercially-available feeds or food products.
- the composition contained in the present invention may be fed to any mammalian or avian species.
- the methods of the invention comprise augmenting immune function in mammalian and avian species.
- the present invention may be added to feeds in amounts ranging from 0.1 to 5 kg per ton of feed.
- the invention may be added to feeds in amounts ranging from 1-2 kg per ton of feed.
- composition contained in the present invention may be added to animal feedstuffs or to foods in amounts ranging from 0.0125% to 2% by weight of feed.
- the composition is added to animal feedstuffs or to food in amounts from 0.0625% to 1% by weight of feed.
- the invention is added in amounts from 0.125% to 0.5% by weight of feed.
- the composition contained in the present invention may be fed directly to mammalian or avian species as a supplement in amounts 0.016 grams/kg to 0.37 grams/kg of live body weight per day.
- the invention may be provided to mammalian and avian species in amounts of 0.10 grams/kg to 0.20 grams/kg of body weight per day.
- the amount of the invention fed can vary depending upon the animal species, size of the animal and type of the feedstuff to which the invention is added.
- the novel methods of this invention comprise the ability of a combination of ⁇ -1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and clay to augment immune function.
- the benefits resulting from the application of the invention to mammalian species include, but are not limited to, reduced death losses, reduced incidence of mycotic abortion, reduced incidence of jejunal hemorrhage syndrome (dead gut syndrome), reduced incidence of scouring (diarrhea), improved growth rate, improved efficiency of growth, improved milk production, improved efficiency of milk production and reduced somatic cell counts in milk products (dairy animals).
- the benefits from the application of the invention to avian species include, but are not limited to, reduced death losses, improved growth and egg production, improved fertility, and reduced incidence of enteric diseases. The following are intended to be illustrative of the invention, and are not to be considered restrictive of the scope of the invention as otherwise described herein.
- Treatments 2, 3, 4 and 5 Animals were fed a dairy-type diet for a period of 28 days. Immunosuppression was mediated in Treatments 2, 3, 4 and 5 by daily injection of Azium using a high dose (a model of extreme stress: Weber et al., 2001). Sheep on Treatments 4 and 5 were challenged with a pathogenic mold by feeding wheat mill run which had been contaminated with a pathogenic mold ( Aspergillus fumigatus ). Sheep on Treatments 3 and 5 were supplemented with the invention at a rate of 0.5% of their daily dry matter intake. Following 28 days, blood samples were taken via jugular puncture and the neutrophil fractions were isolated using Percoll density gradient centrifugation.
- samples of neutrophil protein were processed using sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blotting using antibodies which are specific for L-selectin and interleukin-1- ⁇ . Relative concentrations of L-selectin and interleukin-1- ⁇ . were assessed using scanning densitometry.
- FIGS. 7 and 8 demonstrate effects of the five experimental treatments on neutrophil L-selectin.
- Injection with Azium caused a marked reduction (P ⁇ 0.05) in L-selectin and provides evidence that Azium injection was, in fact, immunosuppressive.
- Addition of mold to the diets had no effect (P>0.05) on L-selectin concentrations.
- addition of the invention to feed (Treatments 3 and 5) caused restoration (augmentation: P ⁇ 0.05) of L-selectin.
- FIGS. 9 and 10 demonstrate effects of the five experimental treatments on neutrophil interleukin-1- ⁇ concentrations.
- Azium treatment caused a marked reduction (P ⁇ 0.05) in neutrophil interleukin-1- ⁇ concentration.
- This demonstrates that Azium was immunosuppressive.
- the novel invention had no effect (P>0.05) on neutrophil interleukin-1- ⁇ in the absence of a pathogen challenge (i.e., Treatment 3 versus Treatment 2); however, the invention caused a marked increase (P ⁇ 0.05) in neutrophil interleukin-1- ⁇ in the presence of a pathogen challenge (i.e., Treatment 5 versus Treatment 4).
- Interleukin- 1 ⁇ is an important pro-inflammatory cytokine which enables the neutrophil to fulfill its role as a phagocyte.
- Ability of the feed product to restore interleukin- 1 ⁇ in the presence of a pathogen ( A. fumigatus ) demonstrates that pathogens potential effects of the invention on immune function.
- FIG. 11 shows the effects of the five experimental treatments on blood concentrations of A. fumigatus.
- A. fumigatus concentrations were determined using a Sybr-Green real-time quantitative polymerase chain reaction (PCR) assay developed in our laboratory. The results demonstrate that the invention reduced (P ⁇ 0.05) A. fumigatus concentration in blood.
- PCR polymerase chain reaction
- composition of the invention i.e., mineral clay, yeast cell wall extract, diatomaceous earth and ⁇ -1,3 (4)-endoglucanohydrolase
- the invention specifically restores levels of L-selectin and interleukin-1- ⁇ in neutrophils thereby restoring the ability of neutrophils to monitor for the presence of invading pathogens.
- the combination of products augments immunity in mammalian and domestic species and thereby prevents the invasion and colonization of the blood compartment. It represents a mixture which is flowable and easily incorporated into feed products and food products.
- the present invention was effective in achieving its immunostimulatory effects under growth conditions which might be found in mammalian and avian digestive systems where nutrients, moisture, oxygen and elevated temperatures are provided by the host.
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 14/137,141, filed Dec. 20, 2013, which is a continuation of U.S. application Ser. No. 14/035,812, filed Sep. 24, 2013, now U.S. Pat. No. 8,834,868, which is a continuation of U.S. application Ser. No. 13/566,433, filed Aug. 3, 2012, now U.S. Pat. No. 8,568,715, which is a continuation of U.S. application Ser. No. 11/668,375, filed Jan. 29, 2007, now U.S. Pat. No. 8,236,303, which is a divisional of U.S. application Ser. No. 10/829,633, filed Apr. 5, 2004, now abandoned.
- This disclosure relates to methods and compositions for the augmentation of immune function in mammalian and avian species.
- The immune system consists of two general features. These are: 1) the innate immune system and 2) the adaptive (antibody-mediated) immune system. The innate system represents the first line of defense against an invading pathogen (whether bacterial or fungal) and provides the adaptive immune system with enough time (3-5 days) for it to build up antibodies which are used to “fight” pathogens. While the innate and adaptive systems are often described separately, they function in tandem; striving to sequester and neutralize a pathogen challenge.
- The innate immune system. The innate immune system consists of several interesting components: Aspects include:
- 1. Physical and chemical barriers to pathogens provided by epithelium, gastric acid and digestive enzymes.
- 2. Cells which engulf and digest invading pathogens (e.g., neutrophils).
- 3. Receptors on the surface of these cells which recognize and bind to pathogens.
- 4. Signaling molecules (e.g., chemokines, cytokines) which communicate sites of infection and regulate expression of immune genes.
- Neutrophils. Neutrophils are among the most important cells of the innate immune system. They are the first cell to arrive at a site of infection. In mammals, there are billions of neutrophils of which about one-half are freely circulating in the blood (Burton and Erskine, 2003). The remainder are held in reserve in bone marrow where they are formed. Neutrophils express an extracellular binding protein on their membranes termed “L-selectin” (also termed CD62L). The role of L-selectin is to interact weakly with the endothelial cell wall thereby allowing the neutrophil to “roll” along the wall of a blood vessel and to “monitor” the cell wall for the presence of signals which indicate a local infection (
FIG. 1 ). The presence of pathogens in peripheral tissues causes release of local chemicals which then signal a rolling neutrophil of an infection. In response to these signals, L-selectin is shed from the surface of the neutrophil (seeFIG. 1 ) and other more adhesive molecules are expressed on its surface. These molecules essentially “glue” the neutrophil within the blood vessel adjacent to the site of infection. The activated neutrophil then migrates through the endothelial cell wall toward the invading pathogen. Interleukin-1β is produced by the neutrophil as a pro-inflammatory cytokine. This aids in mediating inflammation and in facilitating containment of invading pathogens. During neutrophil migration, chemical signals originating from the site of infection (such as TNF-β and interferon y) activate the neutrophil to become a mature “killer cell”. The mature neutrophil migrates toward the site of infection where it interacts with pathogen-associated microbial patterns (PAMPs) on the surface of pathogens via several types of receptors. These receptors are expressed on the surface of the neutrophil and include the following well-identified types (FIG. 2 ): - a—CD18 and CD14
- b—Toll-like receptors (TLRs)
- c—C3b and C3bi (complement factors)
- d—Fc
- Binding of neutrophils to pathogens via receptors. Both CD14 and CD18 receptors bind with lipopolysaccharide (LPS), a common polysaccharide structure associated with membranes of gram-negative bacteria. In addition, neutrophils express toll-like receptors (TLRs) which recognize and bind to additional structures associated with pathogens. So far, ten different toll-like receptors have been identified in mammals (
FIG. 2 and Table 1). TLRs play a critical role in early innate immunity to invading pathogens by sensing microorganisms. These evolutionarily conserved receptors recognize highly conserved structural motifs only expressed by microbial pathogens, called pathogen-associated microbial patterns (PAMPs: Invivogen, 2004). Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK (FIG. 2 ). This signaling cascade leads to the activation of the transcription factor NF-kB which induces the secretion of cytokines that direct the adaptive (i.e., antibody-mediated) immune response. TLRs are predominantly expressed in tissues involved in immune function, such as spleen and peripheral blood leukocytes, as well as those exposed to the external environment such as lung and the gastrointestinal tract. Ten human and nine mouse TLRs have been characterized, seven of which have had their ligands identified. For example, TLR2 is essential for the recognition of a variety of PAMPs, including bacterial lipoproteins, peptidoglycan, and lipotechoic acids. TLR3 is implicated in virus-derived double-stranded RNA. TLR4 is predominantly activated by lipopolysaccharide. TLR5 detects bacterial flagellin and TLR9 is required for response to unmethylated CpG DNA (Table 1). Recently, TLR7 and TLR8 were shown to recognize synthetic antiviral molecules. These receptors are essential elements in host defense against pathogens by activating the innate immunity (Invivogen, 2004). - Bovine TLRs. Relatively few studies on PAMPs have been completed with bovine cells. So far, bovine immune cells have been reported to contain TLR2 and TLR4 (Werling et al., 2004). Polymorphisms have been reported in bovine TLR4 which may determine susceptibility to bovine respiratory disease and Johne's disease (White et al., 2003).
- C3b and C3bi are components of the complement cascade whereas the Fc receptor binds to the “constant region” of antibodies. Hence, pathogens which are coated with complement factors or antibody (i.e., pathogens which are opsonized) are also recognized by activated neutrophils and are subsequently phagocytosed. In other words, activated neutrophils possess several means by which they recognize pathogens (Table 1).
- Phagocytosis and killing. The binding of neutrophils, (and other phagocytic cells) to cell-surface markers of pathogens via these receptors, then permits the phagocytic cell to engulf the invading pathogen and “kill” it (
FIG. 3 ). Presently, two mechanisms for “killing” are known. These include: 1) an oxidative burst, where the phagocyte expresses reactive oxygen species which destroy the phagocytosed pathogen, and 2) fusion of the engulfed pathogen with a lyso some-like structure to form a “phagosome”. The phagosome is rich in digestive enzymes which mediate complete digestion of pathogens. - Common infections. Mammalian and avian species are continually challenged by pathogens in the gastrointestinal track and in the lung. These are important sites for resident neutrophils where minimize pathogen invasion. In addition, the mammary gland of mammals represents a site for pathogen challenge. In all infections, the innate immune system plays a key initial role in fighting-off the initial immune challenge. The innate system is essential to allow the adaptive (antibody-mediated) system to develop and mount a more-specific and directed immune response.
- Cooperation between the innate and acquired immune system in ruminants. Antibodies which are specific to an invading pathogen leak into a site of infection to optimize clearance of a pathogen. Individuals with a high titer against a specific antigen are able to deliver these antibodies into the site of infection via a leaky endothelium (arising from an inflammatory response). Arrival of reactive antibodies (i.e., IgG2) in the alveolus coats (opsonizes) the pathogen and, as noted previously, allows neutrophil recognition of pathogens via Fc receptors (Table 1) and phagocytosis.
- Stress and immune function. Stress reduces individuals' abilities to fight disease. The negative effects of stress on the immune system are mediate by the steroidal stress hormones (Cortisol, hydrocortisone and corticosterone). Burton and co-workers at Michigan State University (Weber et al., 2001) have identified the mechanism by which stress brings about a reduction in immune function. Specifically, they have documented that glucocorticoids (i.e., cortisol) “spike” near parturition (
FIG. 4 ) and reduce L-selectin expression in neutrophils (FIG. 5 ). This compromises one important aspect of an individual's first line-of-defense against pathogen challenge. Specifically, a stressed, immunosuppressed individual has reduced ability to monitor endothelial cell lining for sites of infection and to attack and to sequester pathogens. This may result in an infection (FIG. 6 ). - The object of the present invention is to provide a novel and previously unknown method for augmentation of the immune system in mammalian and avian species. The invention may be applied to, but not limited to, mammalian and avian species and will reduce susceptibility of an individual to both fungal and bacterial diseases.
- A further object of this invention is to provide a method for augmentation of immune function and to thereby minimize or obviate morbidities and mortalities caused by, but not limited to, pathogenic fungi and bacteria with a preparation comprising a combination of β-1,3 (4)-endoglucanohydrolase, β-glucan, diatomaceous earth, glucomannan, and mineral clay, such as aluminum silicate, montmorillonite clay, bentonite or zeolite.
- Another object of the invention is to provide a composition comprising a combination of β-1,3 (4)-endoglucanohydrolase, β-glucan, diatomaceous earth, mineral clay, and glucomannan, which additively augments immune function and thereby, reduces potential of pathogenic fungi and bacteria to cause morbidities and mortalities in mammalian and avian species.
- Additional objects, advantages and novel features of the invention will be set forth, in part, in the description that follows and will, in part, become apparent to those skilled in the art upon examination of the following or may be learned with the practice of the invention. To achieve the foregoing and other objects, and in accordance with the purposes of the present invention as described herein, a novel method is described for the augmentation of immune function of mammalian and avian species. In particular, this invention increases expression of neutrophil L-selectin and interleukin-1β and thereby minimizes or eliminates the colonization of the epithelial surfaces and underlying parenchymal tissues by pathogenic fungi and bacteria, reduces the populations of pathogenic organisms in blood and thereby minimizes or eliminates pathologies directly caused by and indirectly caused by this colonization. The invention comprises a mixture of β-1,3 (4)-endoglucanohydrolase, β-glucan, diatomaceous earth, mineral clay, and glucomannan. The diatomaceous earth is standard commercial grade available from a variety of sources. The β-1,3 (4)-endoglucanohydrolase is produced from submerged fermentation of a strain of Trichoderma longibrachiatum. The β-1,3 (4)-glucan and glucomannan are derived from a commercial product and are an extraction from any of a number of yeast organisms. The mineral clay product is a standard commercial grade (examples include, but are not limited to, montmorillonite clay, bentonite and zeolite). Extractions and productions of diatomaceous earth, yeast cell wall extract and mineral clay are well known in the art and commercially-available.
- The compositions which are provided by the invention can be fed to any mammalian or avian species including, but not limited to, bovine, equine, ovine, caprine and avian species. When admixed with the feed or food or fed as a supplement, the invention augments immune function thereby reducing colonization by pathogens. The invention also minimizes or eliminates invasion of the blood compartment by pathogenic fungi and bacteria. The invention thereby minimizes or eliminates the manifestations of the pathologies typically associated with epithelial and systemic fungal and bacterial infections. Administration of the product may be used as a prophylactic (i.e., to prevent colonization and growth of pathogenic fungal and bacterial species in mammalian or avian species), as an additive to feeds or foods infected with pathogenic fungi or bacteria or as a preferred method to treat and thereby minimize or eliminate an existing, diagnosed or non-diagnosed, fungal or bacterial infection. Application of the invention as described herein and via the specific and novel mechanisms described herein will minimize and possibly eliminate manifestations of fungal and bacterial infections. Application of the invention as described herein will also minimize or possibly eliminate manifestations associated with the presence of pathogenic fungal and bacterial organisms, as identified above, in food or feed of mammalian and avian species.
- The accompanying drawings and photographs which are incorporated into the following “Detailed Description of the Invention” form part of the specification and illustrate several aspects of the present invention and, together with the Detailed Description, serve to explain the details of the invention.
-
FIG. 1 is a schematic drawing illustrating the movement of neutrophils through a blood vessel. L-selectin (CD62L) is shown as circles on the surface of the neutrophils A-E. These allow docking of the neutrophils with endothelium. There is shedding of L-selectin and migration of neutrophil into peripheral tissue toward a site of infection F. (Source: Burton and Erskine, 2003.) -
FIG. 2 is a schematic diagram illustrating toll-like receptors (TLRs) on the surface of an immune cell, and signal transduction following binding of TLRs with microbial PAMPs (pathogen-associated molecular patterns). (Source: M. Adib-Conquy, C. Fitting, 2002.) -
FIG. 3 illustrates a macrophage cell engulfing a bacterium in a process called phagocytosis. Toll-like and other receptor direct phagocytes to recognize microbes. Pseudopodial projections surround the bacterium. (Source: Travis, 2002.) -
FIG. 4 is a bar graph of cortisol levels in dairy cattle relative to day of parturition. Cortisol peaks at day of parturition. (Source: Weber et al., 2001.) -
FIG. 5 is a bar graph of neutrophil surface CD62L (L-selectin) expression in cattle relative to day of parturition. (Source: Weber et al., 2001.) -
FIG. 6 is a schematic diagram illustrating neutrophils lacking L-selectin expression in a stressed dairy cow. (Source: Burton and Erskine, 2003. -
FIG. 7 . Effect of five experimental treatments on concentrations of neutrophil L-selectin. An experiment was conducted with 60 sheep. Twelve sheep were allocated to each treatment. The treatments consisted of: - 1. Control
- 2. Immunosuppressed (daily injections of Azium [Dexamethasone], 0.1 mg/kg twice/day).
- 3. Immunosuppressed plus experimental product fed at 0.5% of daily dry matter intake.
- 4. Immunosuppressed plus moldy feed (addition of Aspergillus fumigatus-infected wheat mill run; 1.5 lbs/head/day).
- 5. Immunosuppressed plus moldy feed (as in Treatment 4) plus the experimental feed product as outlined in
Treatment 3. - The duration of the trial was 28-days. On Day 28, blood was taken from six sheep per treatment and neutrophils were recovered by Percoll gradient centrifugation. The concentrations of L-selectin were determined by Western blot analysis using an antibody specific to L-selectin. Relative concentrations of L-selectin among the five treatment groups are shown in
FIG. 8 . -
FIG. 8 . Scanning densitometry of data shown inFIG. 7 . -
FIG. 9 . Analysis of neutrophil interleukin-1β in the same sheep neutrophil samples presented inFIG. 7 . -
FIG. 10 . Scanning densitometry of data shown inFIG. 9 . -
FIG. 11 . Concentrations of Aspergillus fumigatus in blood samples taken from sheep on Day 28 of the above study. A. fumigatus DNA levels were assessed using a quantitative Sybr-Green PCR-based assay specific for A. fumigatus. - The present invention is based on the novel discovery that a combination of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4)-glucan, diatomaceous earth, mineral clay, and glucomannan effectively augments immune function and reduces colonization of tissues and blood by a pathogen.
- The β-1,3 (4)-endoglucanohydrolase is from a commercial source and is produced from submerged fermentation of a strain of Trichoderma longibrachiatum.
- The diatomaceous earth is prepared by methods commonly known in the art. It is available as a commercially-available acid-washed, product with 95% silica (SiO2) and with its remaining components not assayed but consisting primarily of ash (minerals) as defined by the Association of Analytical Chemists (AOAC, 2002).
- The yeast cell wall extract is prepared by a method commonly known in the art. It is a commercial source of β-1,3 (4) glucan and glucomannan derived from primary inactivated yeast (Saccharomyces cerevisiae) with the following chemical composition:
- Moisture 2-3%
- Dry matter 97-98%
- Proteins 14-17%
- Fats 20-22%
- Phosphorus 1-2%
- Mannans 22-24%
- β-1, 3-(4) glucan 24-26%
- Ash 3-5%
- The mineral clays (aluminosilicates) used in this invention may be fulfilled by any of a variety of commercially-available clays including, but not limited to, montmorillonite clay, bentonite and zeolite.
- In a preferred embodiment of the invention, β-1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.05-3%, 1-40%, 1-20% and 40-92%, respectively. In a preferred composition, β-1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.1-3%, 5-40%, 2-10% and 40-80%, respectively. In an especially preferred embodiment of the invention, β-1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and mineral clay are combined at 0.2-3%, 30-40%, 4-6% and 50-65%, respectively. The preferred physical form of the invention is a dry, free-flowing powder which is suitable for direct inclusion into a feed, food product or as a supplement to a total mixed ration or diet.
- The compositions provided by the present invention may be incorporated directly into commercially-available feeds or food products or fed as supplements to commercially-available feeds or food products. The composition contained in the present invention may be fed to any mammalian or avian species. The methods of the invention comprise augmenting immune function in mammalian and avian species. When incorporated directly into feeds, the present invention may be added to feeds in amounts ranging from 0.1 to 5 kg per ton of feed. In an especially preferred composition, the invention may be added to feeds in amounts ranging from 1-2 kg per ton of feed.
- The composition contained in the present invention may be added to animal feedstuffs or to foods in amounts ranging from 0.0125% to 2% by weight of feed. In a preferred embodiment, the composition is added to animal feedstuffs or to food in amounts from 0.0625% to 1% by weight of feed. In an especially preferred embodiment, the invention is added in amounts from 0.125% to 0.5% by weight of feed.
- Alternatively, the composition contained in the present invention may be fed directly to mammalian or avian species as a supplement in amounts 0.016 grams/kg to 0.37 grams/kg of live body weight per day. In an especially preferred embodiment, the invention may be provided to mammalian and avian species in amounts of 0.10 grams/kg to 0.20 grams/kg of body weight per day. One of skill in the art can appreciate that the amount of the invention fed can vary depending upon the animal species, size of the animal and type of the feedstuff to which the invention is added.
- The novel methods of this invention comprise the ability of a combination of β-1,3 (4)-endoglucanohydrolase, diatomaceous earth, yeast cell wall extract and clay to augment immune function. The benefits resulting from the application of the invention to mammalian species include, but are not limited to, reduced death losses, reduced incidence of mycotic abortion, reduced incidence of jejunal hemorrhage syndrome (dead gut syndrome), reduced incidence of scouring (diarrhea), improved growth rate, improved efficiency of growth, improved milk production, improved efficiency of milk production and reduced somatic cell counts in milk products (dairy animals). The benefits from the application of the invention to avian species include, but are not limited to, reduced death losses, improved growth and egg production, improved fertility, and reduced incidence of enteric diseases. The following are intended to be illustrative of the invention, and are not to be considered restrictive of the scope of the invention as otherwise described herein.
- An experiment was conducted using 60 growing male and female sheep. Sheep were allocated to one of the five treatments (seven females and five males per treatment):
- 1. Control.
- 2. Immunosuppressed (daily injections of Azium [Dexamethasone], 0.1 mg/kg twice/day).
- 3. Immunosuppressed plus the invention fed at 0.5% of daily dry matter intake.
- 4. Immunosuppressed plus moldy feed (addition of Aspergillus fumigatus-infected wheat mill run; 1.5 lbs/head/day).
- 5. Immunosuppressed plus moldy feed (as in Treatment 4) plus the invention as outlined in
Treatment 3. - Animals were fed a dairy-type diet for a period of 28 days. Immunosuppression was mediated in
Treatments Treatments Treatments -
FIGS. 7 and 8 demonstrate effects of the five experimental treatments on neutrophil L-selectin. Injection with Azium caused a marked reduction (P<0.05) in L-selectin and provides evidence that Azium injection was, in fact, immunosuppressive. Addition of mold to the diets had no effect (P>0.05) on L-selectin concentrations. Of interest, addition of the invention to feed (Treatments 3 and 5) caused restoration (augmentation: P<0.05) of L-selectin. - Interpretation: The novel invention successfully restored (augmented) normal levels neutrophil L-selectin. Restoration of L-selectin on neutrophil surfaces will re-establish their ability to monitor the endothelial lining for pathogens.
-
FIGS. 9 and 10 demonstrate effects of the five experimental treatments on neutrophil interleukin-1-β concentrations. Azium treatment caused a marked reduction (P<0.05) in neutrophil interleukin-1-β concentration. This demonstrates that Azium was immunosuppressive. The novel invention had no effect (P>0.05) on neutrophil interleukin-1-β in the absence of a pathogen challenge (i.e.,Treatment 3 versus Treatment 2); however, the invention caused a marked increase (P<0.05) in neutrophil interleukin-1-β in the presence of a pathogen challenge (i.e.,Treatment 5 versus Treatment 4). - Interpretation. Interleukin-1β is an important pro-inflammatory cytokine which enables the neutrophil to fulfill its role as a phagocyte. Ability of the feed product to restore interleukin-1β in the presence of a pathogen (A. fumigatus) demonstrates that pathogens potential effects of the invention on immune function.
-
FIG. 11 shows the effects of the five experimental treatments on blood concentrations of A. fumigatus. A. fumigatus concentrations were determined using a Sybr-Green real-time quantitative polymerase chain reaction (PCR) assay developed in our laboratory. The results demonstrate that the invention reduced (P<0.05) A. fumigatus concentration in blood. - Interpretation. The restoration of neutrophil function shown in
FIGS. 7-10 manifests itself by reducing pathogen load detected within the blood compartment. The invention reduces pathogen load. - These results show that the composition of the invention (i.e., mineral clay, yeast cell wall extract, diatomaceous earth and β-1,3 (4)-endoglucanohydrolase) is capable of a previously-undescribed effect of augmenting immune function. The invention specifically restores levels of L-selectin and interleukin-1-β in neutrophils thereby restoring the ability of neutrophils to monitor for the presence of invading pathogens.
- The combination of products augments immunity in mammalian and domestic species and thereby prevents the invasion and colonization of the blood compartment. It represents a mixture which is flowable and easily incorporated into feed products and food products. The present invention was effective in achieving its immunostimulatory effects under growth conditions which might be found in mammalian and avian digestive systems where nutrients, moisture, oxygen and elevated temperatures are provided by the host.
- The foregoing description of the preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Obvious modifications or variations are possible in light of the above illustrations. The embodiment was chosen and described to provide the best illustration of the principles of the invention and its practical application to thereby enable one of ordinary skill in the art to utilize the invention in various embodiments and with modifications as are suited to the particular use contemplated. All such modifications and variations are within the scope of the invention as determined by the appended claims when interpreted in accordance with the breadth to which they are fairly, legally and equitably entitled.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/876,004 US20160129092A1 (en) | 2004-04-05 | 2015-10-06 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/829,633 US20050220846A1 (en) | 2004-04-05 | 2004-04-05 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US11/668,375 US8236303B2 (en) | 2004-04-05 | 2007-01-29 | Use of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US13/566,433 US8568715B2 (en) | 2004-04-05 | 2012-08-03 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/035,812 US8834868B2 (en) | 2004-04-05 | 2013-09-24 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/137,141 US9173926B2 (en) | 2004-04-05 | 2013-12-20 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/876,004 US20160129092A1 (en) | 2004-04-05 | 2015-10-06 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/137,141 Continuation US9173926B2 (en) | 2004-04-05 | 2013-12-20 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160129092A1 true US20160129092A1 (en) | 2016-05-12 |
Family
ID=35054587
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/829,633 Abandoned US20050220846A1 (en) | 2004-04-05 | 2004-04-05 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US11/668,375 Active 2025-09-07 US8236303B2 (en) | 2004-04-05 | 2007-01-29 | Use of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US13/566,433 Expired - Lifetime US8568715B2 (en) | 2004-04-05 | 2012-08-03 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/035,812 Expired - Lifetime US8834868B2 (en) | 2004-04-05 | 2013-09-24 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/137,141 Expired - Fee Related US9173926B2 (en) | 2004-04-05 | 2013-12-20 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/876,004 Abandoned US20160129092A1 (en) | 2004-04-05 | 2015-10-06 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/829,633 Abandoned US20050220846A1 (en) | 2004-04-05 | 2004-04-05 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US11/668,375 Active 2025-09-07 US8236303B2 (en) | 2004-04-05 | 2007-01-29 | Use of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US13/566,433 Expired - Lifetime US8568715B2 (en) | 2004-04-05 | 2012-08-03 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/035,812 Expired - Lifetime US8834868B2 (en) | 2004-04-05 | 2013-09-24 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US14/137,141 Expired - Fee Related US9173926B2 (en) | 2004-04-05 | 2013-12-20 | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
Country Status (1)
Country | Link |
---|---|
US (6) | US20050220846A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3485743A1 (en) * | 2017-11-21 | 2019-05-22 | Ohly GmbH | Endoglucanase-treated glucans |
US10555964B2 (en) | 2014-02-12 | 2020-02-11 | OmniGen Research, L.L.C. | Composition and method for promoting reduction of heat stress in animals |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050180964A1 (en) * | 2003-03-17 | 2005-08-18 | Puntenney Steven B. | Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |
US20050220846A1 (en) | 2004-04-05 | 2005-10-06 | Puntenney Steven B | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US20070036840A1 (en) * | 2005-07-27 | 2007-02-15 | Jose Antonio Matji Tuduri | Phosphorylated glucomannan polysaccharides containing 1-6 and 1-2 linkages increase weight gain in swine |
US8142798B2 (en) * | 2006-04-26 | 2012-03-27 | OmniGen Research, L.L.C. | Augmentation of titer for vaccination in animals |
EP2046347A2 (en) * | 2006-07-20 | 2009-04-15 | Gourmetceuticals, LLC | Phosphorylated glucomannan polysaccharide for receptor mediated activation and maturation of monocyte-derived dendritic cells |
AU2011201420B2 (en) * | 2011-03-29 | 2015-08-13 | Omnigen Research Llc | Beta-1,3(4)-endoglucanohydrolase, beta-1,3(4) glucan, diatomaceous earth, mineral clay and glucomannan to modulate gastrointestinal genes |
US20150209416A1 (en) * | 2014-01-27 | 2015-07-30 | OmniGen Resarch, LLC | Composition and method for co-administration with a growth promotant |
TW201618676A (en) * | 2014-10-01 | 2016-06-01 | 歐姆尼金研究公司 | Compositions and combinations for use as food supplements for animals |
WO2017044832A1 (en) * | 2015-09-09 | 2017-03-16 | Omnigen Research, Llc | A composition and/or combination for aquaculture |
CN109688831A (en) | 2016-09-09 | 2019-04-26 | 奥姆尼根研究有限责任公司 | Feed addictive comprising allicin |
WO2018112361A1 (en) | 2016-12-15 | 2018-06-21 | Nocek James | Antimicrobial yeast preparation and methods for preparation and use thereof |
AU2018212566B2 (en) | 2017-01-24 | 2022-11-24 | OmniGen Research, L.L.C. | Granulated feed supplement and methods for making and using |
WO2018148563A1 (en) | 2017-02-09 | 2018-08-16 | Mclean Derek | Composition comprising silica, mineral clay, glucan and mannans and its administration to mammals |
CN107594133A (en) * | 2017-10-30 | 2018-01-19 | 四川合泰新光生物科技有限公司 | Application of the water-soluble beta glucan in steer ration |
MX2020007706A (en) | 2018-01-24 | 2020-09-14 | Omnigen Res Llc | Empty |
CA3124973A1 (en) | 2018-12-31 | 2020-07-09 | Omnigen Research, Llc | Feed supplements |
CA3186604A1 (en) | 2020-06-12 | 2021-12-16 | Phibro Animal Health Corporation | Composition or combination comprising anionic dietary supplement and 25-hydroxy vitamin d |
US20230310521A1 (en) | 2022-04-01 | 2023-10-05 | Phibro Animal Health Corporation | Combination comprising bacillus and an essential oil and methods for making and using |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757040A (en) * | 1985-04-01 | 1988-07-12 | Research Institute Of Petroleum Processing Sinopec | Class of pillared interlayered clay molecular sieve products with regularly interstratified mineral structure |
US20120041081A1 (en) * | 2006-08-02 | 2012-02-16 | Hammond Neal A | Biogenic Silica from Silica-Containing Plant Material Such as Rice Hulls |
US8236303B2 (en) * | 2004-04-05 | 2012-08-07 | Omnigen Research, Llc | Use of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US9114129B2 (en) * | 2006-04-26 | 2015-08-25 | Omnigen Research, Llc | Augmentation of titer for vaccination in animals |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3939275A (en) * | 1972-03-06 | 1976-02-17 | Smithkline Corporation | Methods and compositions for increasing growth rate and feed efficiency of animals |
DE2243982A1 (en) | 1972-09-07 | 1974-03-28 | Meggle Milchind Gmbh & Co | USE OF HEXAMETHYLENTETRAMINE RHODANIDE AS A MYCOCIDE AND MYCOCIDAL AGENTS CONTAINING THESE COMPOUNDS |
JPS5413496B2 (en) | 1972-10-17 | 1979-05-31 | ||
US4138479A (en) * | 1975-11-07 | 1979-02-06 | Bayer Aktiengesellschaft | Process for the preparation of immunopotentiating agents from components of yeast cell wall material |
US4055667A (en) | 1975-12-03 | 1977-10-25 | Ogilvie Mills Ltd. | Animal feeds |
GB2007685B (en) | 1977-10-11 | 1982-05-12 | Asahi Dow Ltd | Composition for drawn film cold drawn film made of said composition and process for manufacture of said film |
AU533447B2 (en) | 1978-12-18 | 1983-11-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Stretching multi layer film |
US4251519A (en) | 1979-07-30 | 1981-02-17 | Anheuser-Busch, Incorporated | Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels |
US4729902A (en) * | 1983-08-11 | 1988-03-08 | Control Feeds, Inc. | Animal and fowl feed supplement and process of manufacture |
JPS6079932A (en) | 1983-10-07 | 1985-05-07 | Asahi Chem Ind Co Ltd | High-orientation stretchable multi-layer film and manufacture thereof |
US4765992A (en) | 1984-06-01 | 1988-08-23 | Universite De Bordeaux Ii | Stimulation of alcoholic fermentation by adsorption of toxic substances with cell walls |
US4714716A (en) | 1984-11-16 | 1987-12-22 | The Dow Chemical Company | Lightly crosslinked linear olefinic polymer foams and process for making |
ZA86528B (en) | 1985-01-31 | 1986-09-24 | Himont Inc | Polypropylene with free-end long chain branching,process for making it,and use thereof |
DE3541945A1 (en) | 1985-11-27 | 1987-06-04 | Lomapharm Rudolf Lohman Gmbh K | IMMUNOTIMULATING POLYSACCHARIDES FROM CELL CULTURES FROM ECHINACEA PURPUREA (L.) MOENCH AND ECHINACEA ANGUSTIFOLIA, D.C. PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING IT |
US5407751A (en) | 1985-11-29 | 1995-04-18 | American National Can Company | Easy peel film structure especially for retortable lidstock |
JPH0820704B2 (en) | 1988-11-17 | 1996-03-04 | 富士写真フイルム株式会社 | Laminated film |
US5032401A (en) * | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5063066A (en) * | 1990-01-29 | 1991-11-05 | Degussa Corporation | Dietary modifiction to alleviate toxicity in livestock caused by mycotoxins |
US5165946A (en) | 1990-03-07 | 1992-11-24 | Engelhard Corporation | Animal feed additive and method for inactivating mycotoxins present in animal feeds |
GB9007730D0 (en) | 1990-04-05 | 1990-06-06 | Cerestar Holding Bv | Therapeutic compound and composition |
US5272236A (en) | 1991-10-15 | 1993-12-21 | The Dow Chemical Company | Elastic substantially linear olefin polymers |
DD298884A5 (en) | 1990-07-10 | 1992-03-19 | Charite Der Humboldt-Universitaet,De | VACCINES AGAINST VIRAL ANTIGENES AND METHOD OF PREPARING THEM |
US5192547A (en) | 1990-10-01 | 1993-03-09 | Engelhard Corporation | Animal feed containing selected montmorillonite clay as additive and method for selecting the clay |
US5149549A (en) | 1990-11-21 | 1992-09-22 | American Colloid Company | Method and composition for achieving animal weight gain with mycotoxin-contaminated animal food |
US5527573A (en) | 1991-06-17 | 1996-06-18 | The Dow Chemical Company | Extruded closed-cell polypropylene foam |
US5278272A (en) | 1991-10-15 | 1994-01-11 | The Dow Chemical Company | Elastic substantialy linear olefin polymers |
US5346963A (en) | 1993-04-28 | 1994-09-13 | The Dow Chemical Company | Graft-modified, substantially linear ethylene polymers and methods for their use |
US5519009A (en) | 1993-10-01 | 1996-05-21 | Donzis; Byron A. | Solubilized yeast glucan |
JP2756907B2 (en) | 1993-12-28 | 1998-05-25 | 日本製紙株式会社 | Yeast extract composition, method for producing the same, and feed containing the same |
NO300692B1 (en) | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilized branched β-1,3-glucan and its use, as well as the use of unsolubilized branched β-1,3-glucan |
US5871966A (en) * | 1994-05-11 | 1999-02-16 | Novo Nordisk A/S | Enzyme with endo-1,3(4)-β- Glucanase activity |
US6221381B1 (en) | 1994-06-28 | 2001-04-24 | The University Of British Columbia | Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier |
US5670566A (en) | 1995-01-06 | 1997-09-23 | National Starch And Chemical Investment Holding Corporation | Cool-applied hot melt adhesive composition |
US5639492A (en) | 1995-01-13 | 1997-06-17 | Amcol International Corporation | Method and composition for achieving animal weight gain with mycotoxin-contaminated animal food |
IT1279944B1 (en) | 1995-06-09 | 1997-12-23 | Sarti Angela | COMPOUND FOR THE TREATMENT OF ANIMAL EXCEPTIONS |
AUPN398295A0 (en) * | 1995-07-05 | 1995-07-27 | Carlton And United Breweries Limited | Chemical compounds and processes for their production |
RU2093162C1 (en) | 1995-07-19 | 1997-10-20 | Институт биохимии СО РАН | Agent showing immunostimulating effect |
RU2115421C1 (en) | 1995-12-25 | 1998-07-20 | Комиссарова Надежда Александровна | Pharmaceutical composition showing immunomodulating and hypolipidemic effect |
US5698599A (en) | 1996-03-04 | 1997-12-16 | Rj Reynolds Tobacco Company | Method of inhibiting mycotoxin production |
US5922373A (en) | 1997-05-05 | 1999-07-13 | The Ohio State University | Process for preparing a soy protein feed with enhanced nutritional value |
DE19720975A1 (en) | 1997-05-20 | 1998-11-26 | Danubia Petrochem Polymere | Polyolefin foams with high heat resistance |
AUPO758297A0 (en) * | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
US5935623A (en) | 1998-01-15 | 1999-08-10 | Milwhite, Inc. | Use of thermally treated clays in animal feeds |
ATE355751T1 (en) * | 1998-04-17 | 2007-03-15 | Alltech Inc | COMPOSITIONS FOR REMOVAL OF MYCOTOXINS FROM FEED |
WO1999055715A2 (en) | 1998-04-28 | 1999-11-04 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
US6395311B2 (en) | 1998-04-29 | 2002-05-28 | Univera Pharmaceuticals, Inc. | Multicomponent biological vehicle |
AU3985499A (en) | 1998-05-13 | 1999-11-29 | Biomarin Pharmaceutical Inc. | Lytic enzymes useful for treating fungal infections |
US6361844B1 (en) | 1999-01-27 | 2002-03-26 | David T. Ou-Yang | Release article and adhesive article comprising the release article |
NZ509221A (en) | 1999-05-03 | 2003-09-26 | Alltech Inc | An additive containing a mineral clay and a modified yeast cell wall extract for reduction of effects of endophyte-infected forages |
US6541678B2 (en) | 1999-09-27 | 2003-04-01 | Brennen Medical, Inc. | Immunostimulating coating for surgical devices |
US6476003B1 (en) | 2000-11-06 | 2002-11-05 | Immusonic, Inc. | Method for preparing small particle size glucan in a dry material |
US6623866B2 (en) | 2001-04-04 | 2003-09-23 | Exxonmobil Oil Corporation | Multilayer films including anti-block |
US20030007982A1 (en) * | 2001-04-27 | 2003-01-09 | Peter Surai | Novel method for improving antioxidant status of animals consuming feeds contaminated with mycotoxins |
US6660722B2 (en) | 2001-11-30 | 2003-12-09 | Laboratoires Goemar S.A. | Therapeutical treatments |
US20050180964A1 (en) * | 2003-03-17 | 2005-08-18 | Puntenney Steven B. | Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |
US20050227236A1 (en) | 2003-02-10 | 2005-10-13 | Forsberg Neil E | Mold infections |
JP4051006B2 (en) | 2003-06-19 | 2008-02-20 | 株式会社リコー | Recording material and image forming method using the same |
-
2004
- 2004-04-05 US US10/829,633 patent/US20050220846A1/en not_active Abandoned
-
2007
- 2007-01-29 US US11/668,375 patent/US8236303B2/en active Active
-
2012
- 2012-08-03 US US13/566,433 patent/US8568715B2/en not_active Expired - Lifetime
-
2013
- 2013-09-24 US US14/035,812 patent/US8834868B2/en not_active Expired - Lifetime
- 2013-12-20 US US14/137,141 patent/US9173926B2/en not_active Expired - Fee Related
-
2015
- 2015-10-06 US US14/876,004 patent/US20160129092A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757040A (en) * | 1985-04-01 | 1988-07-12 | Research Institute Of Petroleum Processing Sinopec | Class of pillared interlayered clay molecular sieve products with regularly interstratified mineral structure |
US8236303B2 (en) * | 2004-04-05 | 2012-08-07 | Omnigen Research, Llc | Use of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US8834868B2 (en) * | 2004-04-05 | 2014-09-16 | Omnigen Research, Llc | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US9173926B2 (en) * | 2004-04-05 | 2015-11-03 | Omnigen Research, Llc | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
US9114129B2 (en) * | 2006-04-26 | 2015-08-25 | Omnigen Research, Llc | Augmentation of titer for vaccination in animals |
US20120041081A1 (en) * | 2006-08-02 | 2012-02-16 | Hammond Neal A | Biogenic Silica from Silica-Containing Plant Material Such as Rice Hulls |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10555964B2 (en) | 2014-02-12 | 2020-02-11 | OmniGen Research, L.L.C. | Composition and method for promoting reduction of heat stress in animals |
US11419888B2 (en) | 2014-02-12 | 2022-08-23 | OmniGen Research, L.L.C. | Composition and method for promoting reduction of heat stress in animals |
EP3485743A1 (en) * | 2017-11-21 | 2019-05-22 | Ohly GmbH | Endoglucanase-treated glucans |
WO2019101696A1 (en) * | 2017-11-21 | 2019-05-31 | Ohly Gmbh | Endoglucanase-treated glucans |
Also Published As
Publication number | Publication date |
---|---|
US20130017211A1 (en) | 2013-01-17 |
US8236303B2 (en) | 2012-08-07 |
US20050220846A1 (en) | 2005-10-06 |
US9173926B2 (en) | 2015-11-03 |
US8834868B2 (en) | 2014-09-16 |
US8568715B2 (en) | 2013-10-29 |
US20140023633A1 (en) | 2014-01-23 |
US20140112907A1 (en) | 2014-04-24 |
US20070202092A1 (en) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9173926B2 (en) | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function | |
CA2619219C (en) | Use of .beta.-1,3 (4)-endoglucanohydrolase, .beta.-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function | |
Stuyven et al. | Effect of β-glucans on an ETEC infection in piglets | |
US9114129B2 (en) | Augmentation of titer for vaccination in animals | |
US20060239992A1 (en) | Methods and compositions for the inhibition of growth of infectious aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species | |
WO1999000136A1 (en) | Control of acidic gut syndrome | |
US20210267249A1 (en) | Dietary Supplement Comprising Beta-Glucan and Casein Hydrolysate for Improving Health and Growth Performance in a Mammal | |
MX2008001989A (en) | Use ofã-1,3 (4)-endoglucanohydrolase,ã-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function | |
Forsberg | Recent insights into ruminant immune function: effects of stress and immunostimulatory nutritional products | |
Abo-Sriea et al. | International Journal of Veterinary Science and Medicine | |
Garcia Diaz et al. | Cabreira Jobim C, Pratti Daniel JL, Iank Bueno AV et al (2018) Use of live yeast and mannan-oligosaccharides in grain-based diets for cattle: ruminal parameters, nutrient digestibility, and inflammatory response | |
Mahasneh et al. | Effect of Yeast Cell Wall on Gut Health, Immunity and Milk Production of Dairy Cattle in Normal and Heat Stress Conditions. Review | |
Abo-Sriea et al. | Impact of dietary-nucleotides and Saccharomyces cerevisiae-derivatives on growth-performance, antioxidant-capacity, immune-response, small-intestine histomorphometry, caecal-Clostridia, and litter-hygiene of broiler-chickens treated with florfenicol | |
Kim | Algae-derived β-glucan on Gut Health and Immune Responses in Weaned Pigs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: OMNIGEN RESEARCH, LLC, OREGON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PUNTENNEY, STEVEN B.;FORSBERG, NEIL E.;SIGNING DATES FROM 20091023 TO 20091130;REEL/FRAME:036750/0187 |
|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, TEXAS Free format text: SECURITY INTEREST;ASSIGNORS:PHIBRO ANIMAL HEALTH CORPORATION;OMNIGEN RESEARCH, LLC;PRINCE AGRI PRODUCTS, INC.;REEL/FRAME:042877/0441 Effective date: 20170629 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |